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Prognostic significance of xCT polymorphisms and expression in patients
with advanced pancreatic cancer treated with chemotherapy
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The plasma membrane xc- cystine/glutamate transporter mediates cellular uptake of
cystine in exchange for intracellular glutamate and is highly expressed by
pancreatic cancer cells. The xCT gene, encoding the cystine-specific xCT protein
subunit of xc-, is important in regulating intracellular glutathione (GSH) levels, critical
for cancer cell protection against oxidative stress, tumor growth and resistance to
chemotherapeutic agents including platinum. We examined 4 single nucleotide
polymorphisms (SNPs) of the xCT gene in 269 advanced pancreatic cancer patients
who received first line gemcitabine with or without cisplatin or oxaliplatin.
Genotyping was performed using Taqman real-time PCR assays. A statistically
significant correlation was noted between the 3' untranslated region (UTR) xCT
SNP rs7674870 and overall survival (OS): Median survival time (MST) was 10.9
and 13.6 months, respectively, for the TT and TC/CC genotypes (p = 0.027).
Stratified analysis showed the genotype effect was significant in patients receiving
gemcitabine in combination with platinum therapy (n = 145): MST was 10.5 versus
14.1 months for the TT and TC/CC genotypes, respectively (p = 0.013). The 3' UTR
xCT SNP rs7674870 may correlate with OS in pancreatic cancer patients receiving
gemcitabine and platinum combination therapy. Paraffin-embedded core and
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surgical biopsy tumor specimens from 98 patients with metastatic pancreatic
adenocarcinoma were analyzed by immunohistochemistry using an xCT specific
antibody. xCT protein IHC expression scores were analyzed in relation to overall
survival in 86 patients and genotype in 12 patients and no statistically significant
association was found between the level of xCT IHC expression score and overall
survival (p = 0.514). When xCT expression was analyzed in terms of treatment
response, no statistically significant associations could be determined (p = 0.908).
These data suggest that polymorphic variants of xCT may have predictive value,
and that the xc- transporter may represent an important target for therapy in
pancreatic cancer.
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Chapter 1
INTRODUCTION

Pancreatic Adenocarcinoma
In 2011, approximately 44,030 new pancreatic adenocarcinoma cases will be
diagnosed in the United States, with 37,660 estimated resulting deaths [1].
Although accounting for only 3% of all new cases of cancer, pancreatic cancer
continues to be the fourth leading cause of cancer-related death for both men and
women in the United States [1]. The diagnosis of pancreatic adenocarcinoma
portends a poor prognosis with a mortality rate nearly matching its incidence [1].
This is a highly aggressive cancer that causes substantial disease-related morbidity,
metastasizes early in its natural history, and exhibits treatment resistance [2]. While
surgery is the only potentially curative therapeutic modality when a microscopic
margin negative resection is achieved, only 15–20% of patients have resectable
pancreatic cancer. Of these resected early stage pancreatic adenocarcinomas, the
5-year survival rate is only 20% due to eventual development of metastases [3].
Despite advances in conventional multimodality approaches of surgery, radiation
and chemotherapy, mortality rates of pancreatic adenocarcinoma have remained
relatively unchanged for the last two decades and contribute to a five year overall
survival rate of less than 4% [2, 4]. For this reason, understanding the contribution
of molecular mechanisms to disease natural history and identifying novel molecular
markers are important goals in the management of this cancer.
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Molecular Heterogeneity in Pancreatic Cancer
Progressive accumulation of both inherited and acquired mutations leads to the
molecular heterogeneity of pancreatic adenocarcinoma [5]. This genetic
heterogeneity can be considered broadly in terms of three main molecular events:
oncogenic activation driven by genetic mutations, inactivation of tumor suppressor
genes, and inactivation of genome maintenance genes critical to cellular repair
mechanisms [6]. The extensive inter-tumor genetic variability existing from
individual to individual gives rise to multiple permutations of genetic changes. Jones
et al. demonstrated this high complexity of the pancreatic cancer genome by
determining each cancer has an average of 63 somatic alterations, most of which
are point mutations [7]. However, the deregulation of 12 core biological regulatory
processes or pathways underlie these large numbers of functional genetic
alterations in the majority of pancreatic tumors [7]. Due to this considerable degree
of genetic heterogeneity coupled with disappointing survival outcomes with current
available therapies, patients with pancreatic adenocarcinoma are in particular need
of a personalized approach to cancer therapy.

Challenges of Current Therapy of Pancreatic Cancer
The majority of patients present with unresectable late stage locally advanced or
metastatic disease (stage III or IV) that precludes cure by radiotherapy or surgery
and have tumors highly resistant to most chemotherapies [8, 9]. Despite the role of
cytotoxic chemotherapy as the mainstay of pancreatic cancer therapy, most patients
with pancreatic cancer will eventually progress and develop distant metastatic
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disease. For patients with advanced disease, mono- or combination systemic
chemotherapy that is gemcitabine or fluoropyrimidines-based currently is the
standard of care. In metastatic disease, treatment with gemcitabine is associated
with symptom improvement in more than 20% of patients and offers a slight survival
benefit (5.65 versus 4.4 month overall median survival) when compared to patients
treated with 5-fluorouracil [10]. Drug resistance has hindered gains in survival and
kept beneficial effects largely confined to symptom palliation [11].

Role of Platinum Analogues in Pancreatic Cancer
Combination chemotherapy in pancreatic cancer has resulted in improved
outcomes for patients possessing a good functional performance status [12]. The
combination of gemcitabine and a platinum analogue has become first line standard
care treatment of advanced pancreatic cancer patients based on results from a
meta-analysis of randomized trials [13]. While the combination of gemcitabine with
cisplatin has not yielded significant survival benefit over single agent gemcitabine in
Phase III studies [14-16], individuals with certain heritable forms of pancreatic
cancer may exhibit particular disease sensitivity to platinum agents and benefit with
improved responses to this regimen [17-19]. When compared to gemcitabine
monotherapy, the addition of oxaliplatin to gemcitabine in advanced pancreatic
cancer patients has demonstrated clinically significant advantages of superior
response rates, median progression-free survival, and disease-related symptom
palliation [20]. More recently, the drug regimen of 5-fluorouracil, leucovorin,
irinotecan and oxaliplatin (FOLFIRINOX) resulted in more promising results with
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significant overall survival advantage (10.5 months versus 6.9 months, p>0.001)
when compared with single agent gemcitabine. FOLFIRINOX is now considered
the preferred frontline treatment regimen for good performance status patients with
unresectable or metastatic pancreatic adenocarcinoma [12]. The improved clinical
outcomes prompting increased use of platinum analogues in the frontline and
salvage settings warrant further study of underlying molecular pathways particular
to platinum resistance.

Platinum Resistance
Gaining further understanding of drug-resistance mechanisms is essential to
improving the treatment outcome of patients with pancreatic cancer, as the
identification of novel targets could lead to the development of therapeutic
strategies and provide valuable information to optimize patient selection for
particular drugs. Studies in pancreatic cancer have shown that acquired and
intrinsic drug resistance is mediated by multiple mechanisms within or outside the
cell or at the cell membrane resulting from the dysregulated expression of proteins
regulating cell proliferation, death, transport and metabolism of drugs, and DNA
repair [21].Two key DNA repair pathways of nucleotide excision repair and
mismatch repair are thought to be primary drivers determining sensitivity to cisplatin
and its analogues [22]. In vitro studies in ovarian and testis tumor cell lines
demonstrate that deficiency of the excision repair cross-complementation group 1
(ERCC 1) protein, which is required for the excision of damaged DNA, interrupts the
highly conserved nucleotide excision repair DNA repair pathway and leads to

5
decreased cisplatin sensitivity [23, 24]. Mismatch repair pathway (MMR) deficiency
applies to the platinum agents cisplatin and carboplatin. Inherited genetic changes
or acquired defects due to epigenetic silencing results in failure of repair proteins to
recognize mismatched or unmatched DNA base pairs or insertion-deletion loops
and, thus, inability to correct platinum induced DNA damage [25-28].

As a result,

cells become resistant to cisplatin and carboplatin, continuing to proliferate despite
sustaining treatment-generated DNA damage. Oxaliplatin shows only partial cross
resistance to cisplatin in preclinical studies [29]. In addition to causing DNA
damage, preclinical data suggests that cisplatin and oxaliplatin activate cell death
through generation of reactive oxygen species (ROS); another mechanism of both
cisplatin and oxaliplatin resistance results from generation of the intracellular
antioxidant molecule, glutathione (GSH), which mediates elimination of druginduced ROS [29, 30, 31]

Cystine-Glutamate Antiporter (System xc-)
The plasma membrane cystine/glutamate antiporter (system xc-) is an amino acid
transport system consisting of a light protein subunit with specificity for cystine, xCT
(SLC7A11 gene), that is coupled to a ubiquitous non-specific heavy protein subunit
found in other transporters, 4F2hc (SLC3A2 gene) [32]. In human tissues and cells,
system xc- expression has mainly been demonstrated in the pancreas, along with
other cells from the brain, stromal and immune system [33]. A variety of cancer
cells also express system xc-, including prostate cancer, lymphoma, glioma, lung
cancer and pancreatic cancer [34-37]. xCT transports extracellular cystine
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(oxidized form of cysteine) in to cells in exchange for the efflux of glutamate in an
obligate relationship at a 1:1 ratio (Fig 1) [33]. Once inside the cell, the dimeric
amino acid cystine rapidly reduces to cysteine, the rate-limiting substrate for
glutathione biosynthesis [38]. GSH is a tripeptide thiol of glutamate, cysteine and
glycine, functioning as a major protective redox-regulatory molecule against free
radical induced cellular damage, mutagens, toxins, and drugs [39, 40]. GSH is also
co-factor for antioxidant enzymes and, thus, is a major reactive oxygen species
scavenger [41]. Thus, xCT plays a critical role protecting cells by counteracting
conditions of oxidative stress through its regulation of cystine influx and hence
intracellular GSH levels and contributing to cellular detoxification of chemotherapy
[42]. This antiporter keeps the redox relationship between extracellular cystine and
cysteine in equilibrium [33, 43].

Fig. 1. System xc-: Cystine/Glutamate Antiporter and the Pancreatic Cell.
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Pharmacogenomics & Personalization of Cancer Therapy
Pharmacogenomics is the study of how an individual’s genotype influences the
body’s response to drugs and can give insight to drug efficacy in specific patient
populations. The term comes from the words pharmacology and genomics and
represents the intersection of both disciplines. Germline single nucleotide
polymorphisms (SNPs) in the gene encoding the detoxification enzyme, uridine
diphosphate glucuronosyltransferase (UGT) 1A1, have been linked to increased
toxicity to the drug irinotecan [44]. Patients homozygous for theUGT1A1*28 allele
metabolize the excretion of the irinotecan metabolite, SN-38, more slowly and are at
increased risk for neutropenia following this therapy [45, 46]. With FDA approval of
a test to identify individuals carrying this mutation, identification of this genetic
variant illustrates the predictive possibilities of SNPs. These techniques hold
promise for individualizing and optimizing treatments for patients with pancreatic
cancer.

xCT and Chemoresistance
Given the role of xc- system in the maintainance of intracellular GSH, it may play an
important role in cellular resistance to cisplatin, oxaliplatin and other
chemotherapeutic agents. System xc- has been demonstrated to contribute to
chemotherapy resistance in preclinical studies, with resistance of tumor cells to
anticancer drugs correlated with increased GSH levels. The level of xCT
expression can be induced in conditions of oxidative stress and seems also to play
a role in cancer cell proliferation [37]. Microarray gene expression analysis of
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system xc- in 60 human cancer cell lines used by the National Cancer Institute for
drug screening (NCI-60) demonstrated that the level of xCT expression is positively
correlated with sensitivity of tumor cells to anticancer drugs, with its inhibition
compromising both cellular redox defense and resistance to multiple drugs [47]. Lo
et al demonstrated that the highly chemotherapy resistant pancreatic cell line
PANC-1 expresses higher xCT expression in comparison to pancreatic cell lines
MIAPaCa-2 and BxPC-3 [37]. Similar findings of higher xCT expression correlated
with cisplatin resistance also has been demonstrated in resistant human ovarian
cancer and colon cancer cell lines. Further, data from in vitro systems have shown
that inhibition of xCT restores sensitivity to gemcitabine [49]. An understanding of
the pharmacology including the pharmacogenomics of the xc- system is therefore
worthy of further study.

From these preclinical observations, the following hypotheses are made: 1) genetic
variations of the cystine/glutamate transporter are associated with overall survival
and response to chemotherapy in patients with advanced pancreatic cancer treated
with gemcitabine +/- cisplatin and 2) high xCT expression in pancreatic cancer
tissue is associated with a lower overall survival in patients with unresectable
advanced pancreatic cancer.
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Chapter 2
METHODS

Study Population
Patients were initially identified from patients participating in a case-control study of
pancreatic cancer conducted at The University of Texas MD Anderson Cancer
Center (Houston, Texas) from 1999 through 2009. The study was approved by the
institutional review board of University of Texas MD Anderson Cancer Center. The
eligibility criteria included patients having: a diagnosis of a primary pancreatic ductal
adenocarcinoma that was pathologically confirmed at MD Anderson, gave consent
to blood donation, no prior therapy received, and who received first-line single-agent
gemcitabine or gemcitabine in combination with cisplatin or oxaliplatin treatment at
MD Anderson. All patients signed an informed consent for medical record review
and provided a sample of whole blood by peripheral phlebotomy. Clinical,
pathology, and radiographic records of the selected patients were then reviewed
using the institutional electronic medical records database (ClinicStationTM) to
confirm their diagnosis and disease stage. Available outside records which had
been digitally scanned into the system were also reviewed. Patients who were seen
only at their initial visit without subsequent follow up visits at MD Anderson were
excluded. Patients who had pancreatic neuroendocrine tumors were also excluded.
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Clinical Data Collection
Clinical information was retrieved by reviewing patients' medical records and
included gender, age at diagnosis, date of pathologic diagnosis, clinical tumor stage
(resectable, locally advanced, metastasized, and unstaged), serum carbohydrate
antigen 19-9 (CA19-9) values (unit/mL) at diagnosis, patient performance status,
chemotherapy received in the first-line setting at the time of metastasis and date of
death or last follow-up. Overall survival duration was calculated from the time of
pathologic diagnosis to the date of death or last follow-up. The clinical information
was double-checked by different researchers. Clinical response to chemotherapy
was assessed by evaluation of radiographic reports and determination by the
treating physicians as documented in clinical progress notes. The clinical endpoint
was overall survival and treatment response.

Specimen Collection and DNA Extraction
Peripheral lymphocytes were collected from freshly drawn blood by Ficoll–Hypaque
(Amersham Biosciences, Piscataway, NJ) density gradient centrifugation and stored
at –80 °C. The FlexiGene DNA kit (QIAGEN, Valencia, CA) and the Maxwell 16
automated system (Promega, Madison, WI) were used to extract DNA, which was
stored at 4 °C.

Genotyping
Four functional SNPs located in the coding region (synonymous) or the untranslated
region (UTR) of the SLC7A11 gene were selected. The four SNPs included three
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synonymous SNPs of rs35701885, rs4479754, rs6838248 and one 3’-UTR
(untranslated region) SNP rs7674870. The gene, chromosome (Chr) location,
function, amino acid changes and minor allele frequency (MAF) of the 4 SNPs
evaluated in this study are summarized in Table 1.

Table 1. SNPs evaluated
Gene

Chr

dbSNP
rs#

Chr
Position

Genomic
Systematic

Proteomic
Systematic

Function

Wild
type
allele

Variant
allele

MAF
*

SLC7A11

4q28-q32

rs7674870

139308913

Ex12+3709T>C

3’UTR

3’ UTR

A

C

0.35

rs35701885

139323865

Ex8+45G>A

P320P

Synonymous

G

A

0.04

rs4479754

139319822

Ex11-2G>A

S481S

Synonymous

A

G

0.08

rs6838248

139359944

Ex5+26C>G

Ex5+26C>G

Synonymous

C

G

0.331

* Allele frequencies obtained from the national center for biotechnology information dbSNP cancer database.

Genotyping was performed using the Taqman 5′ nuclease assay. Primers and
TaqMan MGB probes were provided by TaqMan SNP Genotyping Assay Services
(Applied Biosystems, Foster City, CA). PCR was performed in a 5-µL total volume
consisting of TaqMan Universal PCR Master Mix, 20 ng of genomic DNA (diluted
with dH2O), and TaqMan SNP genotyping assay mix. Alleles were discriminated by
running end point detection using an ABI Prism 7900HT sequence detection system
and SDS 2.3 software (Applied Biosystems, Foster City, CA). Approximately 10% of
samples were analyzed in duplicate, and inconsistent data were excluded from final
analysis.

12
Immunohistochemistry
In addition to the above described cohort, patients with metastatic pancreatic
adenocarcinoma evaluated at MD Anderson were also identified from their medical
records. Pathology records of these patients were then used to determine the
availability of patient tissue samples. For patients who had a biopsy or surgical
procedure at MD Anderson, their formalin fixed paraffin embedded tissue samples
were requested and obtained from the pathology file room. For patients treated at
MD Anderson who received a biopsy or surgery at other institutions, formalin fixed
paraffin embedded samples from these patients were also requested and obtained
from outside hospitals. All patients had their pathologic samples confirmed by a
pathologist at MD Anderson.

Formulin fixed paraffin-embedded (FFPE) core and surgical biopsy tumor
specimens from 98 patients with metastatic pancreatic adenocarcinoma were
analyzed by immunohistochemistry (IHC). Tissue samples were cut to 4-5 µm thick
sections using an automated Leica RM2255 rotary microtome and mounted on
silanized positively charged slides.

FFPE tissue histology sections were deparaffinized, hydrated and incubated for 120
minutes. Antigen retrieval was performed using steam preheated to 92-97°C and
submerged in 0.01 M Citrate at pH 6. Samples were cooled for 20 minutes at room
temperature and then washed in 4X PBS for 15 minutes. Peroxide blocking was
done with 3% H2O2 in PBS at room temperature for 10 min, followed by washing in
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4X PBS for 15 minutes, and then blocked with normal serum for 20 minutes at room
temperature.

Slides were incubated with a rabbit primary polyclonal antibody against xCT (Novus
Biologicals, LLC, Littleton, CO) at 1:100 dilution at 4°C overnight and then probed at
room temperature for 60 minutes with the secondary antibody Vectastain Elite
(Vector Laboratories, Burlingame, CA). Samples were washed for 5 minutes using
3X PBS and incubated with ABC reagent for 30 minutes. Staining was developed
with 0.05% 3,3'-Diaminobenzidine (DAB) substrate (Invitrogen, a division of Life
Technologies Corporation, Carlsbad, CA) and counterstained with hematoxylin.

Grading of IHC slides
IHC scores were calculated by the product of intensity and extent of xCT expression
by visualization of 6 fields (staining-intensity X percentage of staining-extent). The
intensity of tumor staining for xCT was quantified using a four value intensity score
that was categorized as: absent (score 0, non-expressed), very weak (score 1,
slightly expressed), weak (score 2, expressed), or strong (score 3, highly
expressed). Detection of positive staining in ≤50% or >50% resulted in a respective
score of 1 or 2 for staining extent. Cells with a final score ≥2 were considered
positive for protein expression in cytoplasmic (membrane) staining.
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Survival Measurements
Overall survival was measured from the date of diagnosis to the date of death or
last follow-up. Dates of death were obtained and confirmed using at least one of
the following three methods: Social Security Death Index
(www.deathindexes.com/ssdi.html), inpatient medical records, and the MD
Anderson tumor registry.

Statistical Analysis
The genotype distribution was tested for Hardy-Weinberg equilibrium with the
goodness-of-fit Χ2 test. The heterozygous and homozygous genotypes were
collapsed in the analysis if the frequency of the homozygous mutant was very low or
if the homozygous and heterozygous genotypes had the same direction of effect,
e.g., both had reduced survival time compared to the referent group.

Median survival times (MST) were calculated for all patients. Kaplan-Meier method
was used for survival analyses, groups were compared using log-rank test. Hazard
ratios and 95% confidence intervals (95% CI) were estimated using univariable or
multivariate Cox proportional hazard models. Known or potential prognostic clinical
factors (CA 19-9, race, performance status) were included in the multivariate model
when appropriate. All statistical testing was conducted with SPSS software, version
17.0 (SPSS), and statistical significance was defined as p < 0.05. All tests were two
sided. The false-positive report probability for the observed statistically significant
association was estimated using the methods described by Wacholder et al [50]. A
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prior probability of 25% was considered appropriate given the biologic plausibility
and previous established biostatistical evidence in support of such an association.
The false-positive report probability value for noteworthiness was set as 0.2.

Immunohistochemistry
xCT protein IHC expression scores were analyzed in relation to overall survival and
response to treatment of the patients. Mean differences of groups were analyzed
using the one factor ANOVA test. Dichotomous scoring, with 0 representing
expression scores ≤ 3 and 1 representing expression scores > 3, was also used to
evaluate the association between the protein expression and overall survival of the
patients. Kaplan-Meier method was used for survival analyses, groups were
compared using log-rank test. Cox proportional hazard regression models were
fitted to determine the association between xCT IHC expression and overall
survival. Prognostic variables entered into the model included ECOG performance
status, CA 19-9, and stage.
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Chapter 3
RESULTS

SNP Analysis.
Patient characteristics and clinical predictors
The patient characteristics are summarized in Table 2. There were no significant
differences in overall survival by age, sex, or race of the 269 patients evaluated. Of
them, 148 (55%) patients had metastatic disease (stage 4) and 121 (45%) patients
had locally advanced pancreatic adenocarcinoma (stage 3).

Table 2. SNP Analysis: Patient characteristics (Total n = 269).
Variable
Age
<50
51-60
61-70
>70
Sex
Male
Female
Race
White
Hispanic
Black
Asian
Stage
3
4

Number of
Patients (n)

Percentage (%)

39
67
102
61

14.5
24.9
37.9
22.7

159
110

59.1
40.9

242
14
10
3

90
5.2
3.7
1.1

121
148

45
55
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We identified three prognostic factors that were significantly associated with
improved survival outcomes, which include an earlier disease stage, a lower CA 199 tumor marker, and a better performance status (Table 3). This analysis was
consistent with previously identified independent prognostic factors in advanced
pancreatic cancer published in the literature, demonstrating our patients are a
representative cohort.

Table 3. SNP Analysis: Clinical Prognostic Factors (n=269).

Stage
3
4
*ECOG Performance
Status
0
1
2
CA 19-9
<47
48-500
>500

N.
patients

No.
deaths

MST
(months)

95% CI

121
148

110
138

15.7
9.7

13.8417.63
7.9511.45

p
value
0.002

0.026
29
129
23

24
121
23

15.7
13.2
10.4

13.7717.7
11.6914.77
6.9413.93
0.005

35
93
126

28
86
119

17.8
14.1
11.4

11.4724.13
12.3415.92
9.6513.15

Information was missing from 88 patients.

Genotype and association with OS.
Of the four SNPs evaluated, one showed a significant association with OS, i.e. the
3’ UTR xCT gene SNP, rs7874870. As shown in Figure 2, patients having CC and
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TC genotypes had a significantly better overall survival than the TT genotype, the
median survival time (MST) was 13.7, 13.3, and 10.9 months, respectively (p value
= 0.023). We estimated the false-positive report probability of the xCT SNP
rs7674870 to be 0.077, given a prior probability of 25%. It is below the threshold of
0.20 indicating noteworthiness.

Figure 2. Kaplan-Meier curve of overall survival in all patients by the
rs7674870 genotype. The genotype is indicated by the blue (TT homozygous), red
(TC heterozygous) and the green (CC homozygous) lines.

Because of similar survival, the CC and TC groups were combined for further
statistical analysis. This range of overall survival is comparable with the general
population of pancreatic cancer patients and further confirms our study population is
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a representative cohort. None of the three synonymous SNPs were found to be
significantly associated with OS. The genotype frequencies, MSTs and hazard
ratios (95% CI) are shown in Table 4.

Table 4. OS by genotype.
SNP
rs4479754
AA
AG
GG
AG/GG
rs6838248
CC
CG
GG
rs35701885
GG
GA
AA
GA/AA

Number of
patients (n)

MST (month)

HR (95% CI)

p value
0.646

260
4
1

12.3
5.9
9.2

1.0
1.2 (0.54-2.66)
0.990

82
113
70

12.7
12.3
11.1

200
21
0

12.4
15.1
-

1.0
1.01 (0.85-1.19)
0.543
1.0
0.92 (0.59-1.43)

Stratified analysis showed that this genotype effect remained significant in patients
receiving gemcitabine in combination with platinum analogs, with MST of 10.5
months for the TT genotype and 14.1 months for the TC/CC genotypes (p value =
0.011) (Fig 3).
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Figure 3. Survival by genotype in patients receiving Gemcitabine + Platinum
Therapy

n

The genotype effect was not significant in patients treated with gemcitabine
monotherapy, with MST of 10.9 months for TT and 12.0 months for TC/CC
genotypes (p value = 0.47) (Fig 4).
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Figure 4. Overall survival by genotype in patients receiving first-line
gemcitabine monotherapy.

None of the three synonymous SNPs (rs4479754, rs6838248, and rs35701885)
were found to be significantly associated with OS (Table 4).
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Immunohistochemistry
98 patient samples were available for evaluation by immunohistochemistry (Table
5). All patients had metastatic pancreatic adenocarcinoma. There were no
significant differences in overall survival by age, sex, race or IHC expression score
of the patients evaluated. Clinical treatment history was available for 86 samples
and were eligible for treatment response data analysis. At the time the data were
censored, 79.5% of the patient population had died.

Table 5. Immunohistochemistry: Patient Characteristics (n=86)
Number of Patients
(n)

Percentage
(%)

HR
(95% CI)

Age

p value
0.699

<50
51-60
61-70
>70

16
25
31
14

18.6
29.1
36
16.3

0.995 (0.971-1.020)**

Sex
Male
70.9
61
Female
29.1
25
Race
White
74
86
Hispanic
4
4.7
Black
6
7
Other
2
2.3
Non-white
IHC Score*
Low
36
42.9
High
48
57.1
Stage
4
86
100
*2 samples were not evaluable after staining
**Continuous variable

0.729
1.0
1.111 (0.614-2.007)
0.102
1.0

0.715 (0.479-1.069)
0.782
1.0
0.924 (0.530-1.614)
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There was no statistically significant association between the level of xCT IHC
expression score and MST, with 8.8 month MST for high xCT expression and 8.4
month MST for low xCT expression (p=0.514) (Figure 5, Table 6).

Figure 5. xCT immunohistochemical expression correlated with overall
survival.

Low expression
High expression
p = 0.514

Table 6. xCT IHC and Overall Survival.

Low IHC
Expression
High IHC
Expression
Overall

Number of
patients
44

Number of
deaths
35

MST
(months)
8.8

95% CI
5.48-12.18

54

48

8.4

5.92-10.81

98

83

8.4

6.41-10.32

p value

0.514
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When the mean xCT IHC expression staining score was analyzed in terms of
patient chemotherapy treatment response, no statistically significant associations
could be determined (p = 0.908) (Table7,8). The trend of higher xCT expression,
however, is consistent with our hypothesis that higher xCT expression is correlated
with aggressive disease course and with our overall survival data indicating a
shorter median survival time.

Table 7. Average IHC Score and Chemotherapy Response.
Response
Progressive disease
Partial response
Stable disease
Total

n
37
25
16
78

Mean
3.28
3.12
3.16
3.21

95% CI
2.76-3.82
2.48-3.76
2.42-3.91
2.87-3.55

p value

0.908

Table 8. xCT IHC Expression Correlated to Chemotherapy Response.
Response
Progressive disease
Partial response
Stable disease
TOTAL with
response

Score < 3
n (%)
15 (40.5)
11 (44)
8 (50)
34 (43.6)

Score > 3
n (%)
22 (59.5)
14 (56)
8 (50)
44 (56.4)

Total
n (%)
30
25
16
78

p value

0.514

Stratified analysis of xCT immunohistochemical expression score and survival by
chemotherapy treatment groups of gemcitabine monotherapy and combination
chemotherapy with gemcitabine and platinum containing agent did not show any
significant associations (Table 9, 10).
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Table 9. IHC: Survival Analysis of Patients Treated with Gemcitabine (n=36).

Low IHC
Expression
High IHC
Expression
Overall

Number of Number of
patients
deaths
18
14

MST
(months)
8.83

95% CI
2.81-14.86

18

15

8.57

6.05-11.08

36

29

8.83

6.66-11.00

p value

0.73

Table 10. IHC: Survival Analysis of Patients Treated with Gemcitabine and
Platinum Agent (n=43).

Low IHC
Expression
High IHC
Expression
Overall

Number of
patients
14

Number of
deaths
13

MST
(months)
7.73

95% CI
3.30-12.17

29

27

8.37

1.58-15.15

43

40

7.73

4.41-11.06

p value

0.98
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Chapter 4
DISCUSSION

Genomic variations may have predictive value in determining response to
chemotherapy. In this study, the associations between xCT gene SNP, rs7674870,
and clinical outcomes of patients with advanced pancreatic adenocarcinoma were
evaluated. To our knowledge, these data are the first to suggest that there is an
important role for cystine/glutamate antiporter genes in predicting cisplatin
resistance and in the overall survival of patients with advanced pancreatic cancer.

Our results suggest that the 3’UTR rs7674870 TC/CC genotype was significantly
associated with OS. The rs7674870 TC/CC genotype remained as a significant
predictor for survival after adjusting for all other clinical and genetic factors. Our
results indicate the correlation between this genotype and OS of patients receiving
combination chemotherapy with gemcitabine and platinum analogs in predicting
platinum treatment response.

This study demonstrates that xCT is reliably detectable by immunohistochemistry in
human pancreatic cancer tissue. xCT has the functional role of modulating the
oxidative environment that is critical to protection of the cancer cell against
xenobiotics through its control of cystine uptake and intracellular glutathione levels
[51]. Based on preclinical data that system xc- expression is associated with
gemcitabine resistance, we expected an association of xCT protein expression with
chemotherapeutic response and OS of patients with metastatic pancreatic cancer.
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Based upon our results demonstrating a possible role of xCT genotypic variations in
cisplatin resistance, we expected the patient cohorts treated with combination
therapy of gemcitabine and platinum to have significant differences in survival
based on level of xCT expression. Our data did not show any such significant
associations.

Many factors may be responsible for these results. In vitro preclinical pancreatic
cell line and in vivo functions may not be similar for xCT, and in vitro function may
not be recapitulated in vivo [52]. Given the discrepancy between in vitro and in vivo
xCT function, the availability of three different xCT loss of function mouse models
serve as valuable systems in which to further study xCT function and response to
pharmacologic manipulation. In comparison to the technique of Western blotting,
immunohistochemistry is limiting as a semi-quantitative assay evaluated by visual
assessment which may depend on inter-observer variability and the target of
interest. Further, the immunohistochemical expression of the xCT protein may not
represent the functional properties of this transporter [37].

We postulated that genetic variations of xCT would manifest in changes of the xCT
protein detectable by immunohistochemistry and expected a possible association of
this SNP with xCT protein expression. An exploratory analysis in 12 patient
samples demonstrated higher xCT expression was associated with reduced survival
seen for the TT genotype, which would be consistent with our SNP analysis.
Though results from this small patient cohort only trended toward statistical
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significance, further genotypic-phenotypic correlative studies may be worthy for
future study. Biologically relevant SNPs may not be best studied by protein
expression correlative studies as multiple regulatory steps are involved in the
pathway from gene to protein. Because synonymous SNPs do not produce altered
coding sequences, they are not expected to change the function of the protein
encoded. However, a previous study has demonstrated that a synonymous SNP in
the MDR1 gene results in a protein product with altered drug and inhibitor
interactions [51]. SNPs may also be located at the 3’ and 5’-UTR of DNA. While
these sequences do not translate into proteins, the 3’UTR may contain sequence
motifs crucial for the regulation of transcription, mRNA stability, and cellular location
of the mRNA or the binding of microRNA [52]. Further studies of xCT mRNA
expression through utilization of Northern blotting and microRNAs, evolutionarily
conserved noncoding RNAs that mediate the posttranslational protein modifications
by binding to 3’ untranslated regions, would be particularly insightful [51].

Given the increasing use of platinum analogues in the frontline setting with the
emergence of FOLFIRINOX and continued use of gemcitabine and cisplatin
combination chemotherapy in advanced pancreatic cancer, our study is especially
relevant. With persistent poor survival outcomes for patients with pancreatic
cancer, clearly a need for greater understanding of underlying mechanisms of
chemotherapy resistance exists. This would be important not only for discerning
disease pathogenesis but also for potentially determining new targets of therapy.
xCT may represent a viable novel target in pancreatic cancer.
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Several pharmacologic agents that inhibit system xc- exist [54], exerting therapeutic
effects primarily by interrupting the antiporter function of cystine uptake into the cell.
The resulting state of decreased intracellular cystine levels may lead to cellular
growth inhibition and ultimately cause a state of glutathione depletion, thus reducing
the ability of the cell to detoxify xenobiotics such as chemotherapy [33]. The
established FDA approved anti-inflammatory drug, sulfasalazine, has been studied
as an xCT inhibitor in many different in vitro and in vivo systems. In vitro,
sulfasalazine causes growth inhibition of the MIAPaCa and PANC-1 pancreatic
cancer cell lines [53]. Chung et al. demonstrated that intraperitoneal injection of
sulfasalazine pharmacologically inhibits system xc- in glioma cells, reducing
glutathione levels in tumor tissue and slowing tumor growth in an intracranial
xenograft animal model for human glioma [54]. While sulfasalazine historically
having excellent safety profile, a trial evaluating sulfasalazine in the treatment of
progressing malignant gliomas had to be terminated early after interim analysis
demonstrated significant grade 4 toxicity and patient death on study [55]. Most
recently, the synthesis of several sulfasalazine analogues possessing a more
favorable pharmacologic profile demonstrate promise in expanding therapeutic
options that inhibit system xc- [56].

It is acknowledged that this study has several limitations and that our findings are
hypothesis generating due to its exploratory nature. The large number of patients
with unresectable advanced pancreatic cancer in this study cohort likely reflects a
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referral bias favoring patients with more severe disease at our institution. A
selection bias exists due to the retrospective nature of this study. This study
population was biologically and clinically heterogenic due to the inclusion of patients
with metastatic pancreatic cancer. We evaluated rs7674870 in a patient cohort of
269 patients where 123 received gemcitabine monotherapy and 140 received
gemcitabine-platinum (cisplatin/oxaliplatin) combination chemotherapy. xCT
immunohistochemistry was performed in 98 patients, of whom 36 was treated with
gemcitabine and 43 was treated with gemcitabine-platinum combination. In 12
patients, the association of genotype and immunohistochemical protein expression
was analyzed. Hence, the statistical power in terms of prediction and prognosis is
limited.

Chemotherapy resistance contributes to poor survival outcomes for patients with
advanced pancreatic cancer. Our analyses is one of the first to specifically evaluate
the role of xCT polymorphisms to the chemotherapy sensitivity and survival in
unresectable pancreatic cancer. In conclusion, genotypes of system xc- xCT
transporter genes have potential as predictive biomarkers for cisplatin response and
efficacy in unresectable advanced pancreatic cancer. This study establishes that
human xCT can be reliably detected and qualitatively scored by
immunohistochemistry. Prospective validation of these results in additional
datasets and human functional pharmacologic inhibitor studies are needed.
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